Focused On-demand Library for Lysophospholipid acyltransferase 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6ZNC8

UPID:

MBOA1_HUMAN

Alternative names:

1-acylglycerophosphocholine O-acyltransferase; 1-acylglycerophosphoethanolamine O-acyltransferase; 1-acylglycerophosphoserine O-acyltransferase MBOAT1; Lysophosphatidylserine acyltransferase; Membrane-bound O-acyltransferase domain-containing protein 1

Alternative UPACC:

Q6ZNC8; A9EDQ5; B4DL59; B4E3J4; Q86XC2; Q8N9R5

Background:

Lysophospholipid acyltransferase 1, known by alternative names such as 1-acylglycerophosphocholine O-acyltransferase and Lysophosphatidylserine acyltransferase, plays a pivotal role in the phospholipid remodeling pathway, also known as the Lands cycle. It catalyzes the transfer of acyl groups to lysophospholipids, producing phospholipids essential for cellular functions. This enzyme shows a preference for oleoyl-CoA as the acyl donor, impacting various phospholipids, including lysophosphatidylserine and lysophosphatidylethanolamine.

Therapeutic significance:

Understanding the role of Lysophospholipid acyltransferase 1 could open doors to potential therapeutic strategies, especially considering its involvement in neurite outgrowth and neuronal differentiation. Its precise function in these processes suggests a foundational role in neural development and regeneration.